Review:
I study here https://www.wmrwcpas.com/stmap_38d31d6.html dapoxetine mayo clinic LEVERKUSEN (Alliance News) - German pharmaceutical giant Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) Tuesday said it plans to accelerate the development of five promising drug candidates that are currently undergoing phase I and II clinical studies. The goal is to progress these experimental drugs - in the areas of oncology, cardiology and women\'s health - into phase III clinical studies by 2015.
Evaluation:
Shopping cart
You do not have any products in your shopping cart yet.
